Immuno-Oncology Antibodies Market Size, Report by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Immuno-Oncology Antibodies Market

5.1. COVID-19 Landscape: Immuno-Oncology Antibodies Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Immuno-Oncology Antibodies Market, By Drug Class

8.1. Immuno-Oncology Antibodies Market Revenue and Volume, by Drug Class

8.1.1. Checkpoint Inhibitors

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Bispecific Antibodies

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Antibody-Drug Conjugates (ADCs)

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Immune Agonist Antibodies

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Immuno-Oncology Antibodies Market, By Application

9.1. Immuno-Oncology Antibodies Market Revenue and Volume, by Application

9.1.1. Non-Small Cell Lung Cancer (NSCLC)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Melanoma

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Renal Cell Carcinoma

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Renal Cell Carcinoma

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Triple-Negative Breast Cancer (TNBC)

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Colorectal Cancer (CRC)

9.1.6.1. Market Revenue and Volume Forecast

9.1.7. Hepatocellular Carcinoma (HCC)

9.1.7.1. Market Revenue and Volume Forecast

9.1.8. Hematologic Malignancies (Lymphoma, Leukemia, Myeloma)

9.1.8.1. Market Revenue and Volume Forecast

9.1.9. Bladder Cancer

9.1.9.1. Market Revenue and Volume Forecast

9.1.10. Gastric and Esophageal Cancer

9.1.10.1`. Market Revenue and Volume Forecast

9.1.11. Cervical and Endometrial Cancer

9.1.11.1. Market Revenue and Volume Forecast

9.1.12. Others (Pancreatic, Brain Tumors, Rare Cancers)

9.1.12.1. Market Revenue and Volume Forecast

Chapter 10. Global Immuno-Oncology Antibodies Market, By Mechanism of Action

10.1. Immuno-Oncology Antibodies Market Revenue and Volume, by Mechanism of Action

10.1.1. Immune Checkpoint Blockade

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Immune Cell Redirection

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Tumor Antigen Targeting with Immune Effector Recruitment

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Cytokine Pathway Modulation

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Immune Stimulation via Receptor Agonism

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. Combination of Immune Activation and Cytotoxicity

10.1.6.1. Market Revenue and Volume Forecast

Chapter 11. Global Immuno-Oncology Antibodies Market, By Route of Administration

11.1. Immuno-Oncology Antibodies Market Revenue and Volume, by Route of Administration

11.1.1. Intravenous (IV)

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Subcutaneous (SC)

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Others (e.g., Intratumoral, Intraperitoneal)

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Immuno-Oncology Antibodies Market, By End User

12.1. Immuno-Oncology Antibodies Market Revenue and Volume, by End User

12.1.1. Hospitals

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Cancer Specialty Clinics

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Academic and Research Institutions

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Others (Outpatient Centers, Homecare)

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Immuno-Oncology Antibodies Market, By Distribution Channel

13.1. Immuno-Oncology Antibodies Market Revenue and Volume, by Distribution Channel

13.1.1. Hospital Pharmacies

13.1.1.1. Market Revenue and Volume Forecast

13.1.2. Retail Pharmacies

13.1.2.1. Market Revenue and Volume Forecast

13.1.3. Specialty Pharmacies

13.1.3.1. Market Revenue and Volume Forecast

13.1.4. Others (Clinical Trial Supply, Direct-to-Patient)

13.1.4.1. Market Revenue and Volume Forecast

Chapter 14. Global Immuno-Oncology Antibodies Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Volume Forecast, by Drug Class

14.1.2. Market Revenue and Volume Forecast, by Application

14.1.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.1.4. Market Revenue and Volume Forecast, by Route of Administration

14.1.5. Market Revenue and Volume Forecast, by End User

14.1.6. Market Revenue and Volume Forecast, by Distribution Channel

14.1.7. U.S.

14.1.7.1. Market Revenue and Volume Forecast, by Drug Class

14.1.7.2. Market Revenue and Volume Forecast, by Application

14.1.7.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.1.7.4. Market Revenue and Volume Forecast, by Route of Administration

14.1.8. Market Revenue and Volume Forecast, by End User

14.1.8.1. Market Revenue and Volume Forecast, by Distribution Channel

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Volume Forecast, by Drug Class

14.1.9.2. Market Revenue and Volume Forecast, by Application

14.1.9.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.1.9.4. Market Revenue and Volume Forecast, by Route of Administration

14.1.10. Market Revenue and Volume Forecast, by End User

14.1.11. Market Revenue and Volume Forecast, by Distribution Channel

14.2. Europe

14.2.1. Market Revenue and Volume Forecast, by Drug Class

14.2.2. Market Revenue and Volume Forecast, by Application

14.2.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.2.4. Market Revenue and Volume Forecast, by Route of Administration

14.2.5. Market Revenue and Volume Forecast, by End User

14.2.6. Market Revenue and Volume Forecast, by Distribution Channel

14.2.8. UK

14.2.8.1. Market Revenue and Volume Forecast, by Drug Class

14.2.8.2. Market Revenue and Volume Forecast, by Application

14.2.8.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.2.9. Market Revenue and Volume Forecast, by Route of Administration

14.2.10. Market Revenue and Volume Forecast, by End User

14.2.10.1. Market Revenue and Volume Forecast, by Distribution Channel

14.2.11. Germany

14.2.11.1. Market Revenue and Volume Forecast, by Drug Class

14.2.11.2. Market Revenue and Volume Forecast, by Application

14.2.11.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.2.12. Market Revenue and Volume Forecast, by Route of Administration

14.2.13. Market Revenue and Volume Forecast, by End User

14.2.14. Market Revenue and Volume Forecast, by Distribution Channel

14.2.15. France

14.2.15.1. Market Revenue and Volume Forecast, by Drug Class

14.2.15.2. Market Revenue and Volume Forecast, by Application

14.2.15.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.2.15.4. Market Revenue and Volume Forecast, by Route of Administration

14.2.16. Market Revenue and Volume Forecast, by End User

14.2.16.1. Market Revenue and Volume Forecast, by Distribution Channel

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Volume Forecast, by Drug Class

14.2.17.2. Market Revenue and Volume Forecast, by Application

14.2.17.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.2.17.4. Market Revenue and Volume Forecast, by Route of Administration

14.2.18. Market Revenue and Volume Forecast, by End User

14.2.18.1. Market Revenue and Volume Forecast, by Distribution Channel

14.3. APAC

14.3.1. Market Revenue and Volume Forecast, by Drug Class

14.3.2. Market Revenue and Volume Forecast, by Application

14.3.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.3.4. Market Revenue and Volume Forecast, by Route of Administration

14.3.5. Market Revenue and Volume Forecast, by End User

14.3.6. Market Revenue and Volume Forecast, by Distribution Channel

14.3.7. India

14.3.7.1. Market Revenue and Volume Forecast, by Drug Class

14.3.7.2. Market Revenue and Volume Forecast, by Application

14.3.7.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.3.7.4. Market Revenue and Volume Forecast, by Route of Administration

14.3.8. Market Revenue and Volume Forecast, by End User

14.3.9. Market Revenue and Volume Forecast, by Distribution Channel

14.3.10. China

14.3.10.1. Market Revenue and Volume Forecast, by Drug Class

14.3.10.2. Market Revenue and Volume Forecast, by Application

14.3.10.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.3.10.4. Market Revenue and Volume Forecast, by Route of Administration

14.3.11. Market Revenue and Volume Forecast, by End User

14.3.11.1. Market Revenue and Volume Forecast, by Distribution Channel

14.3.12. Japan

14.3.12.1. Market Revenue and Volume Forecast, by Drug Class

14.3.12.2. Market Revenue and Volume Forecast, by Application

14.3.12.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.3.12.4. Market Revenue and Volume Forecast, by Route of Administration

14.3.12.5. Market Revenue and Volume Forecast, by End User

14.3.12.6. Market Revenue and Volume Forecast, by Distribution Channel

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Volume Forecast, by Drug Class

14.3.13.2. Market Revenue and Volume Forecast, by Application

14.3.13.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.3.13.4. Market Revenue and Volume Forecast, by Route of Administration

14.3.13.5. Market Revenue and Volume Forecast, by End User

14.3.13.6. Market Revenue and Volume Forecast, by Distribution Channel

14.4. MEA

14.4.1. Market Revenue and Volume Forecast, by Drug Class

14.4.2. Market Revenue and Volume Forecast, by Application

14.4.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.4.4. Market Revenue and Volume Forecast, by Route of Administration

14.4.5. Market Revenue and Volume Forecast, by End User

14.4.6. Market Revenue and Volume Forecast, by Distribution Channel

14.4.7. GCC

14.4.7.1. Market Revenue and Volume Forecast, by Drug Class

14.4.7.2. Market Revenue and Volume Forecast, by Application

14.4.7.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.4.7.4. Market Revenue and Volume Forecast, by Route of Administration

14.4.8. Market Revenue and Volume Forecast, by End User

14.4.9. Market Revenue and Volume Forecast, by Distribution Channel

14.4.10. North Africa

14.4.10.1. Market Revenue and Volume Forecast, by Drug Class

14.4.10.2. Market Revenue and Volume Forecast, by Application

14.4.10.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.4.10.4. Market Revenue and Volume Forecast, by Route of Administration

14.4.11. Market Revenue and Volume Forecast, by End User

14.4.12. Market Revenue and Volume Forecast, by Distribution Channel

14.4.13. South Africa

14.4.13.1. Market Revenue and Volume Forecast, by Drug Class

14.4.13.2. Market Revenue and Volume Forecast, by Application

14.4.13.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.4.13.4. Market Revenue and Volume Forecast, by Route of Administration

14.4.13.5. Market Revenue and Volume Forecast, by End User

14.4.13.6. Market Revenue and Volume Forecast, by Distribution Channel

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Volume Forecast, by Drug Class

14.4.14.2. Market Revenue and Volume Forecast, by Application

14.4.14.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.4.14.4. Market Revenue and Volume Forecast, by Route of Administration

14.4.14.5. Market Revenue and Volume Forecast, by End User

14.4.14.6. Market Revenue and Volume Forecast, by Distribution Channel

14.5. Latin America

14.5.1. Market Revenue and Volume Forecast, by Drug Class

14.5.2. Market Revenue and Volume Forecast, by Application

14.5.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.5.4. Market Revenue and Volume Forecast, by Route of Administration

14.5.5. Market Revenue and Volume Forecast, by End User

14.5.6. Market Revenue and Volume Forecast, by Distribution Channel

14.5.7. Brazil

14.5.7.1. Market Revenue and Volume Forecast, by Drug Class

14.5.7.2. Market Revenue and Volume Forecast, by Application

14.5.7.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.5.7.4. Market Revenue and Volume Forecast, by Route of Administration

14.5.8. Market Revenue and Volume Forecast, by End User

14.5.8.1. Market Revenue and Volume Forecast, by Distribution Channel

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Volume Forecast, by Drug Class

14.5.9.2. Market Revenue and Volume Forecast, by Application

14.5.9.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.5.9.4. Market Revenue and Volume Forecast, by Route of Administration

14.5.9.5. Market Revenue and Volume Forecast, by End User

14.5.9.6. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 15. Company Profiles

15.1. Bristol Myers Squibb

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Merck & Co., Inc.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. AstraZeneca

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Sanofi

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Amgen Inc.

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Eli Lilly and Company

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. BeiGene Ltd

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Innovent Biologics

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. MacroGenics

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Zymeworks Inc.

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The major players in the immuno oncology antibodies market include Bristol Myers Squibb, Merck & Co., Inc., Roche Holding AG, AstraZeneca, Pfizer Inc., Regeneron Pharmaceuticals, Sanofi, Novartis AG, Amgen Inc., Gilead Sciences (Incl. Kite Pharma), Eli Lilly and Company, BeiGene Ltd, Innovent Biologics, MacroGenics, Zymeworks Inc., Genmab A/S, Seagen Inc., I-Mab Biopharma, Hengrui Medicine, and Alphamab Oncology.

The driving factors of the immuno oncology antibodies market are the advancements in monoclonal and bispecific antibodies, which enhance the immune system's response against tumors.

North America region will lead the global immuno oncology antibodies market during the forecast period 2025 to 2034.